Hyperemesis Gravidarum Treatment Market – Global Upcoming Demand & Growth Analysis 2018 to 2028

Hyperemesis gravidarum (HG) is the most prevalent cause of hospitalization during the course of pregnancy (mainly first half). Hyperemesis gravidarum is characterized by severe electrolyte imbalance due to nausea, vomiting. Till date, the exact etiology of hyperemesis gravidarum is not known. For mild cases of hyperemesis gravidarum the treatments include use of antacids, rest and some dietary changes. Severe cases often need hospitalization.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.factmr.com/connectus/sample?flag=S&rep_id=2183

Hyperemesis Gravidarum Treatment Market: Segmentation

Tentatively, the global hyperemesis gravidarum treatment market can be segmented on the basis of type of treatment, route of administration and distribution channel.

Based on Type of Treatment, the global hyperemesis gravidarum treatment market is segmented into:

  • Anti-histamine (Diclectin)
  • Prokinetic agent (Metoclopramide, Cisapride)
  • Vitamin-Mineral Supplement Tablets/ Dietary supplements (Pregvit)
  • Anti-reflux medications (Ranitidine, Lansoprazole)
  • Anti-emetic (Ondensetron)
  • Antacid
  • Other measures of treatment (Intravenous Fluid)

Based on Route of Administration (RoA), the global hyperemesis gravidarum treatment market is segmented into:

  • Peroral
  • Intravenous

Based on Distribution Channel, the global hyperemesis gravidarum treatment market is segmented into:

  • Pharmacy
  • Retailers
  • Wholesaler

Hyperemesis Gravidarum Treatment Market: Overview

The dietary supplements and anti-emetic medications are expected to generate significant revenue over the forecast in the global hyperemesis gravidarum treatment market, followed by prokinetic agents.

Request Full Report With TOC@ https://www.factmr.com/connectus/sample?flag=T&rep_id=2183

Regional Outlook

Geographically, the global hyperemesis gravidarum treatment market is segmented into North America, Latin America, Europe, CIS & Russia, Asia-Pacific Excluding Japan, Japan and the Middle East & Africa. North America is expected to be the dominant regional market for hyperemesis gravidarum treatment due to the growing awareness regarding use of prescription drugs.

Key Players

The global Hyperemesis Gravidarum Treatment is highly fragmented with a large number of global players operating. Examples of some of the key players identified in the global hyperemesis gravidarum treatment market are Duchesnay Inc., Ipca Laboratories Ltd., Medichem S.A., Novartis AG, Midatech Pharma US Inc., and Genentech, Inc., among others.

Ask For Customized Report@ https://www.factmr.com/connectus/sample?flag=RC&rep_id=2183

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A, franklin. arnold
Jumeirah Lakes Towers,
Dubai, United Arab Emirates

Matched content

Editor’s pick

Express Press Release Distribution